Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pilocarpine - Controlled Therapeutics

Drug Profile

Pilocarpine - Controlled Therapeutics

Alternative Names: Pilobuc; Pilocarpine controlled release insert - Controlled Therapeutics

Latest Information Update: 19 Jun 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Controlled Therapeutics (Scotland)
  • Developer Controlled Therapeutics (Scotland); Marillion Pharmaceuticals
  • Class Alkaloids; Antiglaucomas; Furans; Imidazoles; Miotics; Small molecules
  • Mechanism of Action Muscarinic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Xerostomia

Most Recent Events

  • 19 Jun 2015 Discontinued - Phase-II for Xerostomia in United Kingdom (Buccal)
  • 01 Jun 2010 Pilocarpine buccal insert is still in phase II development for Xerostomia
  • 27 Feb 2008 Controlled Therapeutics' pilocarpine buccal insert licensed to Marillion Pharmaceuticals worldwide for the treatment of xerostomia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top